Open AccessLong-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders
Author(s) -
Jonathan I. Silverberg,
Eric L. Simpson,
Andreas Wollenberg,
Robert Bissonnette,
Kenji Kabashima,
Amy M. DeLozier,
Luna Sun,
Tracy Cardillo,
Fabio P. Nunes,
Kristian Reich
Publication year - 2021
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2021.1273
Subject(s) - medicine , atopic dermatitis , clinical endpoint , eczema area and severity index , dermatology , clinical trial
Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs and symptoms of moderate to severe atopic dermatitis in the 16-week, phase 3 monotherapy studies, BREEZE-AD1 and BREEZE-AD2. Long-term efficacy has not yet been examined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom